These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34434533)
1. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer. Martens-Uzunova ES; Kusuma GD; Crucitta S; Lim HK; Cooper C; Riches JE; Azad A; Ochiya T; Boyle GM; Southey MC; Del Re M; Lim R; Ramm GA; Jenster GW; Soekmadji C J Extracell Vesicles; 2021 Aug; 10(10):e12136. PubMed ID: 34434533 [TBL] [Abstract][Full Text] [Related]
2. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells. Segal CV; Koufaris C; Powell C; Gooderham NJ Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647 [TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide. Soekmadji C; Rockstroh A; Ramm GA; Nelson CC; Russell PJ Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 29105980 [TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806 [TBL] [Abstract][Full Text] [Related]
5. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma. Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751 [TBL] [Abstract][Full Text] [Related]
6. Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Joncas FH; Lucien F; Rouleau M; Morin F; Leong HS; Pouliot F; Fradet Y; Gilbert C; Toren P Prostate; 2019 Nov; 79(15):1767-1776. PubMed ID: 31475741 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Fletcher CE; Sulpice E; Combe S; Shibakawa A; Leach DA; Hamilton MP; Chrysostomou SL; Sharp A; Welti J; Yuan W; Dart DA; Knight E; Ning J; Francis JC; Kounatidou EE; Gaughan L; Swain A; Lupold SE; de Bono JS; McGuire SE; Gidrol X; Bevan CL Oncogene; 2019 Jul; 38(28):5700-5724. PubMed ID: 31043708 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347 [TBL] [Abstract][Full Text] [Related]
9. Role of Testosterone Levels on the Combinatorial Effect of Pillai P; Pooleri GK; Nair SV Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860 [TBL] [Abstract][Full Text] [Related]
10. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7. Chen W; Yao G; Zhou K J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631 [TBL] [Abstract][Full Text] [Related]
11. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299 [TBL] [Abstract][Full Text] [Related]
12. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280 [TBL] [Abstract][Full Text] [Related]
13. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Soekmadji C; Riches JD; Russell PJ; Ruelcke JE; McPherson S; Wang C; Hovens CM; Corcoran NM; ; Hill MM; Nelson CC Oncotarget; 2017 Aug; 8(32):52237-52255. PubMed ID: 28881726 [TBL] [Abstract][Full Text] [Related]
14. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. Lin MF; Meng TC; Rao PS; Chang C; Schonthal AH; Lin FF J Biol Chem; 1998 Mar; 273(10):5939-47. PubMed ID: 9488733 [TBL] [Abstract][Full Text] [Related]
15. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer. Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
18. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512 [TBL] [Abstract][Full Text] [Related]
19. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622 [TBL] [Abstract][Full Text] [Related]
20. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]